P05.02.A (18)F-FACBC PET/MRI in diagnostic assessment of gliomas
BACKGROUND AND THEORY: MRI and histopathological tissue sampling are routinely done as part of the diagnostic work-up of patients with glioma. MRI provides anatomical images with high resolution and excellent soft-tissue contrast. But this modality has limitations in identifying tumor grade, true tu...
Published in: | Neuro-Oncology |
---|---|
Main Author: | |
Format: | Text |
Language: | English |
Published: |
Oxford University Press
2022
|
Subjects: | |
Online Access: | http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9443102/ https://doi.org/10.1093/neuonc/noac174.121 |
id |
ftpubmed:oai:pubmedcentral.nih.gov:9443102 |
---|---|
record_format |
openpolar |
spelling |
ftpubmed:oai:pubmedcentral.nih.gov:9443102 2023-10-09T21:54:16+02:00 P05.02.A (18)F-FACBC PET/MRI in diagnostic assessment of gliomas Pedersen, L K 2022-09-05 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9443102/ https://doi.org/10.1093/neuonc/noac174.121 en eng Oxford University Press http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9443102/ http://dx.doi.org/10.1093/neuonc/noac174.121 © The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com https://academic.oup.com/pages/standard-publication-reuse-rightsThis article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/pages/standard-publication-reuse-rights) Neuro Oncol POSTER PRESENTATIONS Text 2022 ftpubmed https://doi.org/10.1093/neuonc/noac174.121 2023-09-10T00:40:34Z BACKGROUND AND THEORY: MRI and histopathological tissue sampling are routinely done as part of the diagnostic work-up of patients with glioma. MRI provides anatomical images with high resolution and excellent soft-tissue contrast. But this modality has limitations in identifying tumor grade, true tumor extension and differentiate viable tumor tissue from treatment induced changes. PET can provide quantitative information of cellular activity and metabolism, and may therefore have additional value compared to MRI alone. OBJECTIVE: The aim of this study was to find the sensitivity of [(18)F]FACBC PET in gliomas, and evaluate if PET imaging with this tracer can improve differentiation between low-and high-grade gliomas. METHODS: Patients with suspicion of primary (n=19) or recurrent gliomas (n=8) were recruited to this study from St. Olavs hospital, Trondheim University Hospital, Trondheim, and from the University Hospital of North Norway, Tromsø. PET acquisitions (30-45 min post injection) using the amino acid radiotracer [(18)F]FACBC (3 MBq/kg) were performed simultaneously to MRI acquisitions (T1 with and without contrast, FLAIR, and UTE for attenuation correction. The sensitivity of [(18)F]FACBC PET in glioma detection was assessed using histopathology as reference. Tumor-to-background ratios (TBRs) were compared to tumor subtype and grade to assess the diagnostic value of this tracer for glioma diagnostics. RESULTS: Histopathology revealed 2 WHO grade 1 gliomas (pilocytic astrocytoma n=1, pilocytic astrocytoma/ganglioglioma n=1), 7 WHO grade 2 gliomas(astrocytoma n=4, oligodendroglioma n=3), 7 WHO grade 3 gliomas(astrocytoma n=5, oligodendroglioma n=2) and 12 WHO grade 4 tumors(astrocytoma n=1, glioblastoma n=11). [(18)F]FACBC PET provided a sensitivity of 74.1% in the detection of gliomas. PET uptake was observed in all grade 4 tumors, 5/7 grade 3 tumors, 2/7 grade 2 tumors, and all grade 1 tumors. TBR(peak) was high with a median value of 9.4 (range: 2.1-34.9) in PET positive tumors. Only tumors with a ... Text North Norway Tromsø PubMed Central (PMC) Norway Tromsø Neuro-Oncology 24 Supplement_2 ii36 ii36 |
institution |
Open Polar |
collection |
PubMed Central (PMC) |
op_collection_id |
ftpubmed |
language |
English |
topic |
POSTER PRESENTATIONS |
spellingShingle |
POSTER PRESENTATIONS Pedersen, L K P05.02.A (18)F-FACBC PET/MRI in diagnostic assessment of gliomas |
topic_facet |
POSTER PRESENTATIONS |
description |
BACKGROUND AND THEORY: MRI and histopathological tissue sampling are routinely done as part of the diagnostic work-up of patients with glioma. MRI provides anatomical images with high resolution and excellent soft-tissue contrast. But this modality has limitations in identifying tumor grade, true tumor extension and differentiate viable tumor tissue from treatment induced changes. PET can provide quantitative information of cellular activity and metabolism, and may therefore have additional value compared to MRI alone. OBJECTIVE: The aim of this study was to find the sensitivity of [(18)F]FACBC PET in gliomas, and evaluate if PET imaging with this tracer can improve differentiation between low-and high-grade gliomas. METHODS: Patients with suspicion of primary (n=19) or recurrent gliomas (n=8) were recruited to this study from St. Olavs hospital, Trondheim University Hospital, Trondheim, and from the University Hospital of North Norway, Tromsø. PET acquisitions (30-45 min post injection) using the amino acid radiotracer [(18)F]FACBC (3 MBq/kg) were performed simultaneously to MRI acquisitions (T1 with and without contrast, FLAIR, and UTE for attenuation correction. The sensitivity of [(18)F]FACBC PET in glioma detection was assessed using histopathology as reference. Tumor-to-background ratios (TBRs) were compared to tumor subtype and grade to assess the diagnostic value of this tracer for glioma diagnostics. RESULTS: Histopathology revealed 2 WHO grade 1 gliomas (pilocytic astrocytoma n=1, pilocytic astrocytoma/ganglioglioma n=1), 7 WHO grade 2 gliomas(astrocytoma n=4, oligodendroglioma n=3), 7 WHO grade 3 gliomas(astrocytoma n=5, oligodendroglioma n=2) and 12 WHO grade 4 tumors(astrocytoma n=1, glioblastoma n=11). [(18)F]FACBC PET provided a sensitivity of 74.1% in the detection of gliomas. PET uptake was observed in all grade 4 tumors, 5/7 grade 3 tumors, 2/7 grade 2 tumors, and all grade 1 tumors. TBR(peak) was high with a median value of 9.4 (range: 2.1-34.9) in PET positive tumors. Only tumors with a ... |
format |
Text |
author |
Pedersen, L K |
author_facet |
Pedersen, L K |
author_sort |
Pedersen, L K |
title |
P05.02.A (18)F-FACBC PET/MRI in diagnostic assessment of gliomas |
title_short |
P05.02.A (18)F-FACBC PET/MRI in diagnostic assessment of gliomas |
title_full |
P05.02.A (18)F-FACBC PET/MRI in diagnostic assessment of gliomas |
title_fullStr |
P05.02.A (18)F-FACBC PET/MRI in diagnostic assessment of gliomas |
title_full_unstemmed |
P05.02.A (18)F-FACBC PET/MRI in diagnostic assessment of gliomas |
title_sort |
p05.02.a (18)f-facbc pet/mri in diagnostic assessment of gliomas |
publisher |
Oxford University Press |
publishDate |
2022 |
url |
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9443102/ https://doi.org/10.1093/neuonc/noac174.121 |
geographic |
Norway Tromsø |
geographic_facet |
Norway Tromsø |
genre |
North Norway Tromsø |
genre_facet |
North Norway Tromsø |
op_source |
Neuro Oncol |
op_relation |
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9443102/ http://dx.doi.org/10.1093/neuonc/noac174.121 |
op_rights |
© The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com https://academic.oup.com/pages/standard-publication-reuse-rightsThis article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/pages/standard-publication-reuse-rights) |
op_doi |
https://doi.org/10.1093/neuonc/noac174.121 |
container_title |
Neuro-Oncology |
container_volume |
24 |
container_issue |
Supplement_2 |
container_start_page |
ii36 |
op_container_end_page |
ii36 |
_version_ |
1779317790220484608 |